These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20409618)

  • 1. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
    Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
    Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
    Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
    Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
    J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.
    Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM
    Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.
    Triola G; Wetzel S; Ellinger B; Koch MA; Hübel K; Rauh D; Waldmann H
    Bioorg Med Chem; 2009 Feb; 17(3):1079-87. PubMed ID: 18321716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
    Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
    J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
    Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new fluorescent xanthines as kinase inhibitors.
    Kim D; Jun H; Lee H; Hong SS; Hong S
    Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
    Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
    Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
    Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
    Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
    George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
    Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
    Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
    Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.